Published Studies on the Use of Thymidine Kinase Determination in Hematological Malignancies

Votava T, Topolcan O, Holubec L Jr, Cerna Z, Sasek L, Finek J, Kormunda S.
Changes of serum thymidine kinase in children with acute leukemia.
Anticancer Res. 2007 Jul-Aug; 27(4A):1925-8.

Seiler T, Dohner H, Stilgenbauer S.
Risk stratification in chronic lymphocytic leukemia.
Semin Oncol. 2006 Apr; 33(2):186-94. Review.

Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E.
Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies.
Haematologica. 2005 Mar; 90(3):391-9. Review.

Madewell BR.
Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma.
J Vet Intern Med. 2004 Sep-Oct; 18(5):595-6.

Magnac C, Porcher R, Davi F, Nataf J, Payelle-Brogard B, Tang RP, Oppezzo P, Levy V, Dighiero G, Ajchenbaum-Cymbalista F.
Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL.
Leukemia. 2003 Jan;17(1):133-7.

Jahrsdorfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G.
Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
J Leukoc Biol. 2002 Jul; 72(1):83-92.

Di Raimondo F, Giustolisi R, Lerner S, Cacciola E, O'Brien S, Kantarjian H, Keating MJ.
Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine.
Ann Oncol. 2001 May; 12(5):621-5.

Scudla V, Budikova M, Bacovsky J, Ordeltova M, Opichalova D, Heincova V.
Relation of the soluble cytoadhesion molecules VCAM-1 and ICAM-1 to selected clinical and laboratory indicators in multiple myeloma (Czech)
Vnitr Lek. 1999 Oct; 45(10):583-90.

Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I, Thiel E, Emmerich B.
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.
Blood. 1999 Mar 1; 93(5):1732-7.

Poley S, Stieber P, Nussler V, Pahl H, Fateh-Moghadam A.
Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Anticancer Res. 1997 Jul-Aug; 17(4B):3025-9.

Poley S, Stieber P, Nussler V, Pahl H, Fateh-Moghadam A.
Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
Anticancer Res. 1997 Jul-Aug; 17(4B):3021-4.

Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, Schick HD, Kuhn-Hallek I, Emmerich B.
Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Leuk Lymphoma. 1996 Aug; 22(5-6):439-47.

Sadamori N.
Clinical and biological significance of serum tumor markers in adult T-cell leukemia (Review).
Leuk Lymphoma. 1996 Aug; 22(5-6):415-9.

Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, Schick HD, Kuhn-Hallek I, Emmerich B.
Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Leuk Lymphoma. 1996 Aug; 22(5-6):439-47.

Aul C, Germing U, Gattermann N, Sohngen D, Heyll A.
The prognostic significance of serum thymidine kinase in the myelodysplastic syndrome (German)
Dtsch Med Wochenschr. 1996 Sep 13; 121(37):1113-8.

Musto P, Bodenizza C, Falcone A, D'Arena G, Scalzulli P, Perla G, Modoni S, Parlatore L, Valvano MR, Carotenuto M.
Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia.
Br J Haematol. 1995 May; 90(1):125-30.

Rehn S, Gronowitz JS, Källander CFR, Sundström C, Glimelius B.
Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
Br J Cancer. 1995 May; 71(5):1099-105.

Suki S, Swan F Jr, Tucker S, Fritsche HA, Redman JR, Rodriguez MA, McLaughlin P, Romaguera J, Hagemeister FB, Velasquez WS, et al.
Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase.
Leuk Lymphoma. 1995 Jun; 18(1-2):87-92.

Musto P, Bodenizza C, Falcone A, D'Arena G, Scalzulli P, Perla G, Modoni S, Parlatore L, Valvano MR, Carotenuto M.
Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia.
Br J Haematol. 1995 May; 90(1):125-30.

Bogni A, Cortinois A, Grasselli G, Seregni E, Crippa F, Castellani MR, Bombardieri E.
Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients.
J Biol Regul Homeost Agents. 1994 Oct-Dec; 8(4):121-5.

Hallek M, Wanders L, Strohmeyer S, Emmerich B.
Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications (Review).
Ann Hematol. 1992 Jul; 65(1):1-5.

Doi S, Naito K, Yamada K.
Serum deoxythymidine kinase as a progressive marker of hematological malignancy.
Nagoya J Med Sci. 1990 Mar; 52(1-4):19-26.

Martinsson U, Glimelius B, Hagberg H, Sundström C.
Prognostic relevance of serum-markers in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin lymphomas.
Eur J Haematol. 1988 Apr; 40(4):289-98.

Källander CFR, Simonsson B, Gronowitz JS, Nilsson K.
Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia.
Eur J Haematol. 1987 Apr; 38(4):331-7.

Källander CFR, Simonsson B, Hagberg H, Gronowitz JS.
Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia.
Cancer. 1984 Dec 1; 54(11):2450-5.

Hagberg H, Glimelius B, Gronowitz S, Killander A, Kallander C, Schroder T.
Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis.
Scand J Haematol. 1984 Jul; 33(1):59-67.

To read PDF files you need Acrobat Reader.